Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
3(100.0%)
3Total
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06654596Not ApplicableRecruiting

Efficacy and Safety of Telitacicept in IgAN

Role: collaborator

NCT06753318Not ApplicableNot Yet Recruiting

Validation of Joint-AI in Diagnosing Pancreatic Solid Lesions

Role: collaborator

NCT03916432Not ApplicableUnknown

HELIOS China Registry: Evaluation of the HELIOS Stent in a 'Real-World' Patient Population

Role: collaborator

All 3 trials loaded